-
Something wrong with this record ?
Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances
L. Mráziková, S. Hojná, A. Pačesová, L. Hrubá, V. Strnadová, B. Neprašová, B. Železná, J. Kuneš, L. Maletínská
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
Springer Nature OA/Free Journals
from 2011-01-01
Springer Nature - nature.com Journals - Fully Open Access
from 2011-01-01
- MeSH
- Diabetes Mellitus, Type 2 * drug therapy MeSH
- Glucose MeSH
- Prolactin-Releasing Hormone pharmacology therapeutic use MeSH
- Insulin therapeutic use MeSH
- Rats MeSH
- Leptin * MeSH
- Mice MeSH
- Obesity metabolism MeSH
- Body Weight MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND/OBJECTIVE: Anorexigenic palmitoylated prolactin-releasing peptide (palm11-PrRP) is able to act centrally after peripheral administration in rat and mouse models of obesity, type 2 diabetes mellitus and/or neurodegeneration. Functional leptin and intact leptin signaling pathways are necessary for the body weight reducing and glucose tolerance improving effect of palm11-PrRP. We have previously shown that palm11-PrRP31 had glucose-lowering properties but not anti-obesity effect in Koletsky rats with leptin signaling disturbances, so improvements in glucose metabolism appear to be completely independent of leptin signaling. The purpose of this study was to describe relationship between metabolic and neurodegenerative pathologies and explore if palm11-PrRP31 could ameliorate them in obese fa/fa rat model with leptin signaling disruption. SUBJECT/METHODS: The fa/fa rats and their age-matched lean controls at the age 32 weeks were used for this study. The rats were infused for 2 months with saline or palm11-PrRP31 (n = 7-8 per group) at a dose of 5 mg/kg per day using Alzet osmotic pumps. During the dosing period food intake and body weight were monitored. At the end of experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected and arterial blood pressure was measured. Then, markers of leptin and insulin signaling, Tau phosphorylation, neuroinflammation, and synaptogenesis were measured by western blotting and immunohistochemistry. RESULTS: Fa/fa rats developed obesity, mild glucose intolerance, and peripheral insulin resistance but not hypertension while palm11-PrRP31 treatment neither lowered body weight nor attenuated glucose tolerance but ameliorated leptin and insulin signaling and synaptogenesis in hippocampus. CONCLUSION: We demonstrated that palm11-PrRP31 had neuroprotective features without anti-obesity and glucose lowering effects in fa/fa rats. This data suggest that this analog has the potential to exert neuroprotective effect despite of leptin signaling disturbances in this rat model.
1st Faculty of Medicine Charles University Prague Czech Republic
Institute of Organic Chemistry and Biochemistry CAS Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018365
- 003
- CZ-PrNML
- 005
- 20250924094417.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41387-022-00205-3 $2 doi
- 035 __
- $a (PubMed)35589696
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Mráziková, Lucia $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic $7 xx0307846
- 245 10
- $a Palmitoylated prolactin-releasing peptide treatment had neuroprotective but not anti-obesity effect in fa/fa rats with leptin signaling disturbances / $c L. Mráziková, S. Hojná, A. Pačesová, L. Hrubá, V. Strnadová, B. Neprašová, B. Železná, J. Kuneš, L. Maletínská
- 520 9_
- $a BACKGROUND/OBJECTIVE: Anorexigenic palmitoylated prolactin-releasing peptide (palm11-PrRP) is able to act centrally after peripheral administration in rat and mouse models of obesity, type 2 diabetes mellitus and/or neurodegeneration. Functional leptin and intact leptin signaling pathways are necessary for the body weight reducing and glucose tolerance improving effect of palm11-PrRP. We have previously shown that palm11-PrRP31 had glucose-lowering properties but not anti-obesity effect in Koletsky rats with leptin signaling disturbances, so improvements in glucose metabolism appear to be completely independent of leptin signaling. The purpose of this study was to describe relationship between metabolic and neurodegenerative pathologies and explore if palm11-PrRP31 could ameliorate them in obese fa/fa rat model with leptin signaling disruption. SUBJECT/METHODS: The fa/fa rats and their age-matched lean controls at the age 32 weeks were used for this study. The rats were infused for 2 months with saline or palm11-PrRP31 (n = 7-8 per group) at a dose of 5 mg/kg per day using Alzet osmotic pumps. During the dosing period food intake and body weight were monitored. At the end of experiment the oral glucose tolerance test was performed; plasma and tissue samples were collected and arterial blood pressure was measured. Then, markers of leptin and insulin signaling, Tau phosphorylation, neuroinflammation, and synaptogenesis were measured by western blotting and immunohistochemistry. RESULTS: Fa/fa rats developed obesity, mild glucose intolerance, and peripheral insulin resistance but not hypertension while palm11-PrRP31 treatment neither lowered body weight nor attenuated glucose tolerance but ameliorated leptin and insulin signaling and synaptogenesis in hippocampus. CONCLUSION: We demonstrated that palm11-PrRP31 had neuroprotective features without anti-obesity and glucose lowering effects in fa/fa rats. This data suggest that this analog has the potential to exert neuroprotective effect despite of leptin signaling disturbances in this rat model.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a tělesná hmotnost $7 D001835
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
- 650 _2
- $a glukosa $7 D005947
- 650 _2
- $a inzulin $x terapeutické užití $7 D007328
- 650 12
- $a leptin $7 D020738
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a obezita $x metabolismus $7 D009765
- 650 _2
- $a hormon uvolňující prolaktin $x farmakologie $x terapeutické užití $7 D056690
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hojná, Silvie $u Institute of Physiology CAS, Prague, Czech Republic
- 700 1_
- $a Pačesová, Andrea $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
- 700 1_
- $a Hrubá, Lucie $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
- 700 1_
- $a Strnadová, Veronika $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
- 700 1_
- $a Neprašová, Barbora $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u Institute of Physiology CAS, Prague, Czech Republic $7 xx0335496
- 700 1_
- $a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic
- 700 1_
- $a Kuneš, Jaroslav $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic $u Institute of Physiology CAS, Prague, Czech Republic
- 700 1_
- $a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry CAS, Prague, Czech Republic. maletin@uochb.cas.cz $1 https://orcid.org/0000000342998983
- 773 0_
- $w MED00181736 $t Nutrition & diabetes $x 2044-4052 $g Roč. 12, č. 1 (2022), s. 26
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35589696 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20250924094412 $b ABA008
- 999 __
- $a ok $b bmc $g 1822116 $s 1169608
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 1 $d 26 $e 20220519 $i 2044-4052 $m Nutrition & diabetes $n Nutr Diabetes $x MED00181736
- LZP __
- $a Pubmed-20220720